CD38 enzymatic and receptor inhibition regulated CD43 and galectin-1 expression, CD45 activityhi populations, and CLL proliferation, while leaving Th cells largely unaffected. This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.